Management and outcomes of patients on maintenance dialysis during the first and second wave of the COVID-19 pandemic in Geneva, Switzerland.


Journal

Swiss medical weekly
ISSN: 1424-3997
Titre abrégé: Swiss Med Wkly
Pays: Switzerland
ID NLM: 100970884

Informations de publication

Date de publication:
27 08 2021
Historique:
entrez: 8 9 2021
pubmed: 9 9 2021
medline: 14 9 2021
Statut: epublish

Résumé

Patients on maintenance dialysis are at high risk for serious complications from COVID-19 infection, including death. We present an overview of local experience with dialysis unit management and reorganisation, local epidemiology and outcomes during the COVID-19 outbreak in Geneva, Switzerland, where SARS-CoV-2 incidence was one of the highest in Europe. All SARS-CoV-2-positive outpatients on maintenance dialysis were transferred from their usual dialysis facility to the Geneva University Hospitals dialysis unit to avoid creation of new clusters of transmission. Within this unit, appropriate mitigation measures were enforced, as suggested by the institutional team for prevention and control of infectious diseases. From 25 February to 31 December 2020, 82 of 279 patients on maintenance dialysis tested positive for SARS-CoV-2 during two distinct waves, with an incidence rate of 73 cases per 100,000 person-days during the first wave and 342 cases per 100,000 during the second wave, approximately four- to six-fold higher than the general population. The majority of infections (55%) during both waves were traced to clusters. Most infections (62%) occurred in men. Sixteen patients (34%) died from COVID-19 related complications. Deceased patients were older and had a lower body mass index as compared with patients who survived the infection. SARS-CoV-2 is associated with high infection and fatality rates in the dialysis population. Strict mitigation measures seemed to be effective in controlling infection spread among patients on maintenance dialysis outside of clusters. Large scale epidemiological studies are needed to assess the efficacy of preventive measures in decreasing infection and mortality rates within the dialysis population.

Sections du résumé

BACKGROUND
Patients on maintenance dialysis are at high risk for serious complications from COVID-19 infection, including death. We present an overview of local experience with dialysis unit management and reorganisation, local epidemiology and outcomes during the COVID-19 outbreak in Geneva, Switzerland, where SARS-CoV-2 incidence was one of the highest in Europe.
METHODS
All SARS-CoV-2-positive outpatients on maintenance dialysis were transferred from their usual dialysis facility to the Geneva University Hospitals dialysis unit to avoid creation of new clusters of transmission. Within this unit, appropriate mitigation measures were enforced, as suggested by the institutional team for prevention and control of infectious diseases.
RESULTS
From 25 February to 31 December 2020, 82 of 279 patients on maintenance dialysis tested positive for SARS-CoV-2 during two distinct waves, with an incidence rate of 73 cases per 100,000 person-days during the first wave and 342 cases per 100,000 during the second wave, approximately four- to six-fold higher than the general population. The majority of infections (55%) during both waves were traced to clusters. Most infections (62%) occurred in men. Sixteen patients (34%) died from COVID-19 related complications. Deceased patients were older and had a lower body mass index as compared with patients who survived the infection.
CONCLUSION
SARS-CoV-2 is associated with high infection and fatality rates in the dialysis population. Strict mitigation measures seemed to be effective in controlling infection spread among patients on maintenance dialysis outside of clusters. Large scale epidemiological studies are needed to assess the efficacy of preventive measures in decreasing infection and mortality rates within the dialysis population.

Identifiants

pubmed: 34495598
doi: 10.4414/SMW.2021.w30006
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Ido Zamberg (I)

Division of Anaesthesiology, Department of Anaesthesiology, Pharmacology, Intensive care and Emergency Medicine, Geneva University Hospitals, Geneva, Switzerland.

Thomas Mavrakanas (T)

Division of Nephrology, Department of Medicine, McGill University, Montreal, Canada.
Division of Nephrology, Department of Medicine, Geneva University Hospitals, Geneva, Switzerland.

Thomas Ernandez (T)

Division of Nephrology, Department of Medicine, Geneva University Hospitals, Geneva, Switzerland.
Dialysis Unit, Hôpital de la Tour, Meyrin, Switzerland.

Vincent Bourquin (V)

Dialysis Unit, Hôpital de la Tour, Meyrin, Switzerland.
Dialysis Unit, Groupe médical d'Onex, Switzerland.

Michael Zellweger (M)

Dialysis Unit, Groupe médical d'Onex, Switzerland.

Nicolas Marangon (N)

Dialysis Unit, MV Santé, Geneva, Switzerland.

Françoise Raimbault (F)

Division of Nephrology, Department of Medicine, Geneva University Hospitals, Geneva, Switzerland.

Rebecca Winzeler (R)

Swiss Dialysis Registry, Institute of Nephrology, Stadtspital Waid and Triemli, Zurich, Switzerland.

Anne Iten (A)

Infection Control Programme, Geneva University Hospitals, Geneva, Switzerland.

Nathalie Hammer (N)

Division of General Internal Medicine, Department of Medicine, Geneva University Hospitals, Geneva, Switzerland.

Belen Ponte (B)

Division of Nephrology, Department of Medicine, Geneva University Hospitals, Geneva, Switzerland.

Sebastian Carballo (S)

Division of General Internal Medicine, Department of Medicine, Geneva University Hospitals, Geneva, Switzerland.

Pierre-Yves Martin (PY)

Division of Nephrology, Department of Medicine, Geneva University Hospitals, Geneva, Switzerland.

Patrick Saudan (P)

Division of Nephrology, Department of Medicine, Geneva University Hospitals, Geneva, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH